The global market for therapeutic monoclonal antibodies (mAbs) was estimated at $44.6 billion in 2011. With the rollout of at least eight new therapeutic mAb products and expanded indications for existing products expected during the forecast period, the global mAb market is expected to rise at a compound annual growth rate (CAGR) of 5.3% to nearly $58 billion in 2016.
The U.S. is projected to be the largest single market for therapeutic mAbs from 2011 to 2016. This particular market was nearly $19.8 billion in 2010 and reached $20.1 billion by 2011. BCC projects this market will grow to $27.4 billion by 2016, a CAGR of 6.4%.
Sales of mAbs in the rest of the world will remain higher than in the U.S.—despite a higher CAGR in the U.S. versus the rest of the world. This market is expected to grow from $24.6 billion in 2011 to $30.3 billion in 2016 at a CAGR of 4.3%.